CLINICAL TRIALS PROFILE FOR GADOTERATE MEGLUMINE
✉ Email this page to a colleague
All Clinical Trials for GADOTERATE MEGLUMINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00650845 ↗ | Renal Safety Evaluation After Dotarem®-Enhanced MRI | Completed | Guerbet | Phase 4 | 2008-01-01 | Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial. The aim of this study was to evaluate the safety profile of gadoterate meglumine (Dotarem®) in patients with chronic renal insufficiency by evaluating the rate of patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate meglumine. |
| NCT01010932 ↗ | Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) | Completed | Guerbet | Phase 3 | 2009-10-01 | The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease. |
| NCT01012674 ↗ | Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) | Completed | Guerbet | Phase 3 | 2009-10-01 | The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease. |
| NCT01254552 ↗ | Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis | Completed | Guerbet | Phase 4 | 2010-08-01 | The study aimed to prospectively investigate the prevalence of myocardial scar on Dotarem-enhanced Cardiovascular Magnetic Resonance Imaging (MRI) in asymptomatic patients with type-2 Diabetes Mellitus and to assess its correlation with subclinical coronary artery disease on Cardiac Computed Tomography Angiography (CCTA). |
| NCT01449266 ↗ | Safety and Dialysability of Dotarem® in Dialysed Patients | Completed | Guerbet | Phase 1 | 2011-11-01 | To evaluate the dialysability of Dotarem®, after an IV injection of 0.1 mmol/kg in patients with chronic renal failure who require hemodialysis treatment. |
| NCT01806740 ↗ | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC | Terminated | Guerbet | Phase 4 | 2013-05-09 | The main objective is to evaluate the value of dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) in prediction of response of patients with hepatocellular carcinoma (HCC) to treatment with Sorafenib assessed by mRECIST. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GADOTERATE MEGLUMINE
Condition Name
| Condition Name for GADOTERATE MEGLUMINE | |
| Intervention | Trials |
| Breast Diseases | 2 |
| Cerebral Arterial Diseases | 2 |
| Contrast Enhancement in Magnetic Resonance Imaging | 2 |
| Doxorubicin Induced Cardiomyopathy | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for GADOTERATE MEGLUMINE
Trials by Country
Clinical Trial Progress for GADOTERATE MEGLUMINE
Clinical Trial Phase
Clinical Trial Sponsors for GADOTERATE MEGLUMINE
Sponsor Name
